TGS


Guidance: Meningococcal disease enhanced surveillance plan

The national surveillance protocol for invasive meningococcal disease (IMD) in England has been extended in recognition of:

Changes to the meningococcal group C (MCC) conjugate vacciination programme, including the removal of the infant MCC dose at 4 months and the introduction of an adolescent MCC dose in June 2013.

The emergency introduction of a quadrivalent conjugate vaccine against meningococcal groups A, C, W, and Y (MenACWY) for 14-18 year-olds in August 2015 in response to a national outbreak of a hypervirulent MenW.

The introduction of a MenB vaccine, Bexsero®, into the national infant immunisation schedule in September.


Local copy of Meningococcal_surveillance_plan_V1.pdf
Local copy of Meningococcal_surveillance_plan_V1.pdf

https://www.gov.uk/government/publications/meningococcal-disease-enhanced-surveillance-plan

seen at 11:41, 30 August in Publications on GOV.UK.
Email this to a friend.